About this trial
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent.
Stated willingness to comply with all study procedures and availability for the study duration.
Aged 18 to 64 years old.
Weight of at least 110 lbs.
Disqualifiers
Inability to give informed consent.
Refusal or inability to have blood drawn.
Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, platelet disorder requiring precautions).
Pregnant or nursing individuals.
Trial design
Treatments tested in this trial
- Metformin
- Placebo
- Jynneos
- Capvaxvie
Treatment groups
Sponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator